trending Market Intelligence /marketintelligence/en/news-insights/trending/KWsTeCgtC_ptW-CZ6pXpfg2 content esgSubNav
In This List

Sinovac seeks China FDA approval for pneumonia vaccine

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Sinovac seeks China FDA approval for pneumonia vaccine

Sinovac Biotech Ltd. filed an application seeking approval for its lung infection vaccine from the China Food and Drug Administration.

The vaccine will be used to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia, among adults aged 65 or older and children older than two years with serious long-term health problems.

The submission is supported by a phase 3 clinical trial.